Success with B cell depletion using rituximab has proven the concept that B lineage cells
represent a valid target for the treatment of autoimmune diseases, and has promoted the …

The failure of many new, mostly biologic, drugs to meet their primary end points in double-
blind clinical trials in patients with systemic lupus erythematosus (SLE) has caused a …

Objective To evaluate the characteristics of patients with autoimmune disease with
hypogammaglobulinemia following rituximab (RTX) and describe their long-term outcomes …

Rituximab is a chimeric monoclonal antibody used to treat hematologic and autoimmune
diseases by depleting CD20-expressing B cells. Patients may develop …

Rituximab (RTX) is a monoclonal antibody against CD20, commonly used in the treatment of
hematological malignancies and autoimmune diseases. The use of RTX is related to the …

Rituximab is a B cell depleting monoclonal antibody that targets the B cell-specific cell
surface antigen CD20 and is currently used to treat several autoimmune diseases. The …

Background B cells can contribute to immune-mediated disorders. Targeting CD20 has
proved to be efficacious in several B cell-mediated immunopathologies, as illustrated by the …

Objectives To describe the baseline characteristics of SLE patients requiring biologic
therapy in the UK and to explore short term efficacy and infection rates associated with …

Systemic lupus erythematosus (SLE) is a systemic autoimmune condition characterised by a
wide spectrum of clinical manifestations, partly related to the disease itself, but also linked to …

Background B-cell depletion with rituximab induces sustained remission in children with
steroid-dependent or frequently relapsing nephrotic syndrome. However, most patients …